Literature DB >> 11874466

Regulation of RAS in human platelets. Evidence that activation of RAS is not sufficient to lead to ERK1-2 phosphorylation.

David Tulasne1, Teresa Bori, Steve P Watson.   

Abstract

In this study, we show that the G protein-coupled receptor agonist thrombin, the glycoprotein VI agonist convulxin, and the cytokine receptor Mpl agonist thrombopoietin (TPO) are able to induce activation of RAS in human platelets. Recruitment of GRB2 by tyrosine-phosphorylated proteins in response to TPO and convulxin but not by thrombin occurred with a similar time-course to RAS activation, consistent with a causal relationship. On the other hand, activation of ERK2 by thrombin and convulxin is delayed and also inhibited by the protein kinase C inhibitor Ro-31 8220, whereas RAS activation is unaffected. Further evidence for differential regulation of RAS and ERK is provided by the observations that TPO, which activates RAS but not protein kinase C, does not activate ERK, and that the inhibitor of SRC kinases PP1 inhibits activation of RAS but not ERK2 in response to thrombin. Our results demonstrate that activation of RAS is not necessarily coupled to ERK in human platelets.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11874466     DOI: 10.1046/j.1432-1033.2002.02798.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  10 in total

1.  TC21/RRas2 regulates glycoprotein VI-FcRγ-mediated platelet activation and thrombus stability.

Authors:  S Janapati; J Wurtzel; C Dangelmaier; B K Manne; D Bhavanasi; J C Kostyak; S Kim; M Holinstat; S P Kunapuli; L E Goldfinger
Journal:  J Thromb Haemost       Date:  2018-06-08       Impact factor: 5.824

2.  Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs.

Authors:  Özgün Babur; Alexander R Melrose; Jennifer M Cunliffe; John Klimek; Jiaqing Pang; Anna-Liisa I Sepp; Jevgenia Zilberman-Rudenko; Samuel Tassi Yunga; Tony Zheng; Iván Parra-Izquierdo; Jessica Minnier; Owen J T McCarty; Emek Demir; Ashok P Reddy; Phillip A Wilmarth; Larry L David; Joseph E Aslan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

3.  RASA3 is a critical inhibitor of RAP1-dependent platelet activation.

Authors:  Lucia Stefanini; David S Paul; Raymond F Robledo; E Ricky Chan; Todd M Getz; Robert A Campbell; Daniel O Kechele; Caterina Casari; Raymond Piatt; Kathleen M Caron; Nigel Mackman; Andrew S Weyrich; Matthew C Parrott; Yacine Boulaftali; Mark D Adams; Luanne L Peters; Wolfgang Bergmeier
Journal:  J Clin Invest       Date:  2015-02-23       Impact factor: 14.808

4.  Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets.

Authors:  Analia Garcia; Haripriya Shankar; Swaminathan Murugappan; Soochong Kim; Satya P Kunapuli
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

5.  The protein tyrosine phosphatase PTPN7 is a negative regulator of ERK activation and thromboxane generation in platelets.

Authors:  Vaishali V Inamdar; Haritha Reddy; Carol Dangelmaier; John C Kostyak; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2019-07-02       Impact factor: 5.157

Review 6.  RAP GTPases and platelet integrin signaling.

Authors:  Lucia Stefanini; Wolfgang Bergmeier
Journal:  Platelets       Date:  2018-06-04       Impact factor: 3.862

7.  The Phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) Binder Rasa3 Regulates Phosphoinositide 3-kinase (PI3K)-dependent Integrin αIIbβ3 Outside-in Signaling.

Authors:  Anthony M Battram; Tom N Durrant; Ejaife O Agbani; Kate J Heesom; David S Paul; Raymond Piatt; Alastair W Poole; Peter J Cullen; Wolfgang Bergmeier; Samantha F Moore; Ingeborg Hers
Journal:  J Biol Chem       Date:  2016-11-30       Impact factor: 5.157

8.  Critical roles for the phosphatidylinositide 3-kinase isoforms p110β and p110γ in thrombopoietin-mediated priming of platelet function.

Authors:  Samantha F Moore; Nina R Smith; Thomas A Blair; Tom N Durrant; Ingeborg Hers
Journal:  Sci Rep       Date:  2019-02-06       Impact factor: 4.379

Review 9.  Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk.

Authors:  Khadijeh Barzaman; Rana Vafaei; Mitra Samadi; Mohammad Hossein Kazemi; Aysooda Hosseinzadeh; Parnaz Merikhian; Shima Moradi-Kalbolandi; Mohammad Reza Eisavand; Houra Dinvari; Leila Farahmand
Journal:  Cancer Cell Int       Date:  2022-08-19       Impact factor: 6.429

Review 10.  Small GTPases in platelet membrane trafficking.

Authors:  Tony G Walsh; Yong Li; Andreas Wersäll; Alastair W Poole
Journal:  Platelets       Date:  2018-10-26       Impact factor: 3.862

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.